Cytokinetics | CYTK - Ordinary Share Capital


Cytokinetics reported $124.43M in Ordinary Share Capital for its fiscal quarter ending in March of 2026.





Ordinary Share Capital Change Date
Acadia Pharmaceuticals USD 169.18M 470K Dec/2025
Amgen USD 540M 1000K Mar/2026
Arca Biopharma USD 48.72M 338K Dec/2025
Bayer EUR 982.42M 0 Dec/2025
Biogen USD 146.7M 200K Sep/2025
Brainstorm Cell Therapeutics USD 11.04M 2K Dec/2025
Bristol-Myers Squibb USD 2.04B 1.74B Sep/2025
Capricor Therapeutics USD 57.37M 11.65M Dec/2025
Cytokinetics USD 124.43M 2.17M Mar/2026
Eisai JPY 282.11M 0 Mar/2026
Eli Lilly USD 943.5M 3.33M Mar/2026
Exelixis USD 253.7M 8.78M Mar/2026
Geron USD 640.9M 2.54M Mar/2026
Halozyme Therapeutics USD 118.52M 741K Mar/2026
Ionis Pharmaceuticals USD 165.9M 3.93M Mar/2026
Ligand Pharmaceuticals USD 19.66M 19.64M Sep/2025
Merck USD 2.47B 12.72M Dec/2025
Novartis USD 1.91B 60K Mar/2026
Pfizer USD 5.7B 13M Mar/2026
Regeneron Pharmaceuticals USD 105M 300K Mar/2026
Roche Holding CHF 795.62M 699.54K Dec/2025
Sanofi EUR 1.21B 8.25M Mar/2026